A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
Running, not enrolling · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
In brief
This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.
Key facts
- Study ID
- NCT04123626
- Run by
- ProQR Therapeutics
- People needed
- 11
- Starts
- 2019-10-07
- Expected to finish
- 2022-06-07
- Last updated by the study team
- 2022-05-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology — Aurora, Colorado, United States
- VitreoRetinal Associates — Gainesville, Florida, United States
- Shriners UK Ophthalmology - University of Kentucky — Lexington, Kentucky, United States
- Casey Eye Institute, OHSU — Portland, Oregon, United States
- Retina Foundation of the Southwest — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.